Clinical Trial

Role of Neuroinflammation and Blood-Brain Barrier Breakdown in Intracerebral Hemorrhage.

Study acronym: INFINITE
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
In this prospective, multicenter study of patients with acute spontaneous supratentorial Intracerebral Hemorrhage (ICH), each participant will have a standardized multimodal evaluation of neuroinflammation at 10 (±2) days after onset including translocator protein 18 kDa (TSPO) positron emission tomography (PET) using 18F-DPA-714 radioligand, BBB imaging using Dynamic contrast-enhanced (DCE)-MRI and a panel of pro-inflammatory and anti-inflammatory plasma biomarkers.
Trial Details
NCT Number NCT07583147
Lead Sponsor University Hospital, Toulouse
Conditions Intracerebral Hemorrhage
Enrollment 117 participants
Start Date 2026-06
Primary Completion 2029-09 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-13